Pfizer 4Q Revenues: $11.7 billion (+12%) 4Q Earnings: $594 million (loss of $337 million 4Q20) FY Revenues: $41.9 billion (+2%) FY Earnings: $9.6 billion (-41%) Comments: Growth primarily driven by strong performances from Vyndaqel/Vyndamax, Eliquis, Oncology Biosimilars, Ibrance, Prevenar 13 Outside of the U.S., Inlyta, Xeljanz and Xtandi. Vyndaqel/Vyndamax sales were $429 million in the quarter, up 96%. Eliquis alliance revenues and direct sales were $1.3 billion, up 15%. Ibrance sales w...